瀏覽海報時間

MP06-01: Is extraperitoneal extended pelvic lymph node dissection adequate during robotic assisted radical prostatectomy for intermediate and high risk localized prostate cancer?

MP06-02: A single center experience of Abiraterone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel based chemotherapy

MP06-03: Real world experience of androgen deprivation therapy associated bone fracture risk in newly diagnosed prostate cancer patients

MP06-04: Hyperforin induces extrinsic/intrinsic apoptosis signaling and inhibits NF-кB for metastasis suppression in prostate cancer cells

MP06-05: Retzius-sparing robot-assisted radical prostatectomy and extended pelvic lymph node dissection for very high-risk prostate cancer

MP06-06: The analysis of concordance rates between cancer stage of MR/US fusion prostate biopsy and radical prostatectomy specimen

MP06-07: Oncological and functional outcomes in high risk and very high risk prostate cancer patients receiving robotic-assisted radical prostatectomy

MP06-08: Treatment strategy and systemic review with PSMA PET/CT scan in progressive advanced prostate cancer

MP06-09: KCGMH experience and meta-analysis: 6-cycle complete rate of Radium-223 therapy in mCRPC patients with different treatment sequences

MP06-10: Characteristics of mCRPC patients received Abiraterone acetate plus prednisolone and Enzalutamide before chemotherapy